Brief: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran
27/10/2025 13:14
Oct 27 (Reuters) - Intellia Therapeutics Inc NTLA.O: INTELLIA THERAPEUTICS PROVIDES UPDATE ON MAGNITUDE CLINICAL TRIALS OF NEXIGURAN ZICLUMERAN (NEX-Z) INTELLIA THERAPEUTICS INC - PAUSES DOSING AND SCREENING FOR MAGNITUDE TRIALS INTELLIA THERAPEUTICS INC - PAUSE DUE TO GRADE 4 LIVER TRANSAMINASES IN PATIENT Source text: ID:nGNX50DKd0 Further company coverage: NTLA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)